

Ref. No. : JPL/CS/1630/2020

Date : 2<sup>nd</sup> July, 2020.

To  
BSE Ltd.,  
P J Towers,  
Dalal Street,  
Mumbai - 400 001.

Sub. : **Newspapers Publication of Audited Financial Results for the quarter and year ended on 31 March, 2020.**

Dear Sir,


Kindly find enclosed, cuttings of following two Newspapers dated 2<sup>nd</sup> July, 2020 containing the audited financial results of the Company for the quarter and year ended on 31<sup>st</sup> March, 2020.

- (1) The Free Press Journal, Mumbai (English) and
- (2) Navshakti, Mumbai (Marathi).

Kindly acknowledge.

Thanking you,

Yours faithfully,  
For Jenburkt Pharmaceuticals Ltd.,



(Ashish R. Shah)  
Company Secretary.

Encl.: As stated above.

 Science hai toh Hope hai  Hope hai toh Health hai  Health hai toh Happiness hai 





JENBURKT PHARMACEUTICALS LTD.

Regd. Office: Nirmala Apartments., 93, J. P. Road, Andheri (W), Mumbai-400 058

CIN: L24230MH1985PLC036541 + Tel:66943121 + Fax:66943127 + E-mail: investor@jenburkt.com

**EXTRACT OF STANDALONE AUDITED FINANCIAL RESULTS  
FOR THE QUARTER AND YEAR ENDED ON 31/03/2020**

Sr. No.	Particulars	Quarter ended 31.03.20	Quarter ended 31.12.19	Quarter ended 31.03.19	Year ended 31.03.20	Year ended 31.03.19
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1.	Total Income from Operations (Net)	3156.46	3442.84	3605.83	12310.92	12605.40
2.	Net Profit / (Loss) for the period (before tax, Exceptional and Extra ordinary items)	688.92	667.20	939.22	2113.78	2663.34
3.	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items)	688.92	667.20	939.22	2113.78	2663.34
4.	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	461.65	463.88	689.45	1486.96	1979.78
5.	Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period after tax) and other Comprehensive Income (after tax)	200.20	489.31	665.57	1253.57	1952.49
6.	Paid-up Equity Share Capital (F.V. of Rs.10/- each)	458.94	458.94	458.94	458.94	458.94
7.	Reserves and surplus (excluding revaluation reserve)	—	—	—	7541.49	7287.61
8.	Earnings per share (EPS) (F.V. of Rs.10/- each) (for continuing & discontinued operations) (Basic & Diluted)	10.06	10.11	15.02	32.40	43.14

## NOTES:

- The above is an extract of the detailed format of Audited Financial Results for the quarter & financial year ended on 31st March, 2020 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results for the Quarter and Financial Year ended on 31st March, 2020 are available on the website of the Stock Exchange viz. [www.bseindia.com](http://www.bseindia.com) and that of the Company viz. [www.jenburkt.com](http://www.jenburkt.com).
- The figures of the previous period have been regrouped/rearranged to render them comparable with figures of the current period.

By order of the Board  
For JENBURKT PHARMACEUTICALS LTD.

(Ashish U. Bhuta)  
Chairman & Managing Director

Place: Mumbai  
Date: 30/6/2020



JENBURKT PHARMACEUTICALS LTD.

Regd. Office: Nirmala Apartments., 93, J. P. Road, Andheri (W), Mumbai-400 058

CIN: L24230MH1985PLC036541 + Tel:66943121 + Fax:66943127 + E-mail: investor@jenburkt.com

**EXTRACT OF STANDALONE AUDITED FINANCIAL RESULTS  
FOR THE QUARTER AND YEAR ENDED ON 31/03/2020**

(Rs. in Lacs except EPS)

Sr. No.	Particulars	Quarter ended 31.03.20	Quarter ended 31.12.19	Quarter ended 31.03.19	Year ended 31.03.20	Year ended 31.03.19
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1.	Total Income from Operations (Net)	3156.46	3442.84	3605.83	12310.92	12605.40
2.	Net Profit / (Loss) for the period (before tax, Exceptional and Extra ordinary items)	688.92	667.20	939.22	2113.78	2663.34
3.	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items)	688.92	667.20	939.22	2113.78	2663.34
4.	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	461.65	463.88	689.45	1486.96	1979.78
5.	Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period after tax) and other Comprehensive Income (after tax)	200.20	489.31	665.57	1253.57	1952.49
6.	Paid-up Equity Share Capital (F.V. of Rs.10/- each)	458.94	458.94	458.94	458.94	458.94
7.	Reserves and surplus (excluding revaluation reserve)	—	—	—	7541.49	7287.61
8.	Earnings per share (EPS) (F.V. of Rs.10/- each) (for continuing & discontinued operations) (Basic & Diluted)	10.06	10.11	15.02	32.40	43.14

## NOTES:

- The above is an extract of the detailed format of Audited Financial Results for the quarter & financial year ended on 31st March, 2020 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results for the Quarter and Financial Year ended on 31st March, 2020 are available on the website of the Stock Exchange viz. [www.bseindia.com](http://www.bseindia.com) and that of the Company viz. [www.jenburkt.com](http://www.jenburkt.com).
- The figures of the previous period have been regrouped/rearranged to render them comparable with figures of the current period.

By order of the Board  
For JENBURKT PHARMACEUTICALS LTD.

(Ashish U. Bhuta)  
Chairman & Managing Director

Place: Mumbai  
Date: 30/6/2020